You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the NATROBA (spinosad) Drug Profile, 2024 PDF Report in the Report Store ~

NATROBA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Natroba patents expire, and what generic alternatives are available?

Natroba is a drug marketed by Parapro Llc and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the spinosad profile page.

DrugPatentWatch® Generic Entry Outlook for Natroba

Natroba was eligible for patent challenges on January 18, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Drug patent expirations by year for NATROBA
Drug Prices for NATROBA

See drug prices for NATROBA

Drug Sales Revenue Trends for NATROBA

See drug sales revenues for NATROBA

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for NATROBA
Generic Entry Date for NATROBA*:
Constraining patent/regulatory exclusivity:
FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
NDA:
Dosage:
SUSPENSION;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NATROBA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Concentrics ResearchPhase 4
Medpace, Inc.Phase 4
STATKING Clinical ServicesPhase 4

See all NATROBA clinical trials

Pharmacology for NATROBA
Drug ClassPediculicide

US Patents and Regulatory Information for NATROBA

NATROBA is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NATROBA is ⤷  Try a Trial.

This potential generic entry date is based on FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NATROBA

Methods and compositions useful for controlling cutaneous mites
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: THE PRODUCT COMPOSITION (NATROBA) IS FOR THE TOPICAL TREATMENT OF HUMAN SCABIES MITE INFESTATIONS BY MELTING AND DELIVERING THE ACTIVE INGREDIENT, SPINOSAD, TO THE STRATUM CORNEUM WHERE SCABIES MITES LIVE AND BREED

FDA Regulatory Exclusivity protecting NATROBA

FOR THE TOPICAL TREATMENT OF SCABIES INFESTATIONS IN ADULT AND PEDIATRIC PATIENTS 4 YEARS OF AGE AND OLDER
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NATROBA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Try a Trial ⤷  Try a Trial
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Try a Trial ⤷  Try a Trial
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Try a Trial ⤷  Try a Trial
Parapro Llc NATROBA spinosad SUSPENSION;TOPICAL 022408-001 Jan 18, 2011 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for NATROBA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Elanco GmbH Comfortis spinosad EMEA/V/C/002233
Treatment and prevention of flea infestations (Ctenocephalides felis).The preventive effect against re-infestations is a result of the adulticidal activity and the reduction in egg production and persists for up to 4 weeks after a single administration of the product.The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Withdrawn no no no 2011-02-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for NATROBA

See the table below for patents covering NATROBA around the world.

Country Patent Number Title Estimated Expiration
Spain 2263257 ⤷  Try a Trial
Mexico PA02004088 COMPOSICIONES PARA EL TRATAMIENTO PEDICULICIDA Y OVACIDA Y METODOS PARA ELIMINAR PIOJOS Y SUS HUEVOS. (PEDICULICIDAL AND OVACIDAL TREATMENT COMPOSITIONS AND METHODS FOR KILLING HEAD LICE AND THEIR EGGS.) ⤷  Try a Trial
Australia 750046 ⤷  Try a Trial
Japan 2535080 ⤷  Try a Trial
Slovakia 20062000 Prostriedok proti ľudským všiam (FORMULATIONS FOR CONTROLLING HUMAN LICE) ⤷  Try a Trial
Egypt 19191 Macrolide compounds and their use as insecticide ⤷  Try a Trial
Germany 68920301 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NATROBA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0375316 06C0047 France ⤷  Try a Trial PRODUCT NAME: SPINOSAD; REGISTRATION NO/DATE IN FRANCE: 2060098 DU 20060628; REGISTRATION NO/DATE AT EEC: 9275/B DU 20011023
0375316 SPC/GB02/028 United Kingdom ⤷  Try a Trial PRODUCT NAME: SPINOSAD; REGISTERED: CH W 6020 20010313; UK 0714 20020227
0375316 C350009 Netherlands ⤷  Try a Trial PRODUCT NAME: SPINOSAD, DESGEWENST IN DE VORM VAN EEN ZOUT; NATL. REGISTRATION NO/DATE: 12363 N 20020913; FIRST REGISTRATION: SE 4511 20020204
0375316 350009 Netherlands ⤷  Try a Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.